Further  	Further  	 JJ	O
strategies  	strategies  	 NNS	O
for  	for  	 IN	O
treating  	treating  	 VBG	B-NP
fibromyalgia 	fibromyalgia 	 NNS	I-NP
:  	:  	 :	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
serotonin  	serotonin  	 NN	B-NP
and  	and  	 CC	O
norepinephrine  	norepinephrine  	 FW	B-NP
reuptake  	reuptake  	 FW	I-NP
inhibitors  	inhibitors  	 FW	I-NP
Fibromyalgia  	Fibromyalgia  	 NNP	I-NP
and  	and  	 CC	O
associated  	associated  	 JJ	O
conditions  	conditions  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
irritable  	irritable  	 JJ	O
bowel  	bowel  	 JJ	O
syndrome  	syndrome  	 NN	O
and  	and  	 CC	O
temporomandibular  	temporomandibular  	 JJ	B-NP
disorder  	disorder  	 NNS	I-NP
involve  	involve  	 VBP	O
dysfunctions  	dysfunctions  	 VBN	O
in  	in  	 IN	O
central  	central  	 JJ	O
sensitization  	sensitization  	 NN	B-NP
and  	and  	 CC	O
pain  	pain  	 NN	B-NP
modulation 	modulation 	 NN	I-NP
.  	.  	 .	O
Central  	Central  	 JJ	O
nervous  	nervous  	 JJ	O
system  	system  	 NN	B-NP
dysfunction  	dysfunction  	 NNS	I-NP
may  	may  	 MD	O
also  	also  	 RB	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
other  	other  	 JJ	O
symptoms  	symptoms  	 NNS	B-NP
characteristic  	characteristic  	 NN	O
of  	of  	 IN	O
fibromyalgia 	fibromyalgia 	 NN	B-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
fatigue  	fatigue  	 NN	O
and  	and  	 CC	O
sleep  	sleep  	 JJ	B-NP
disturbance 	disturbance 	 NN	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
key  	key  	 JJ	B-NP
neurotransmitters  	neurotransmitters  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
pain  	pain  	 NN	B-NP
modulation  	modulation  	 NN	I-NP
pathway  	pathway  	 NNS	I-NP
are  	are  	 VBP	O
serotonin  	serotonin  	 VBN	O
and  	and  	 CC	O
norepinephrine 	norepinephrine 	 NN	B-NP
.  	.  	 .	O
Preclinical  	Preclinical  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
using  	using  	 VBG	O
animal  	animal  	 JJ	O
models  	models  	 NNS	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
pain  	pain  	 NN	I-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
that  	that  	 IN	O
pharmacologic  	pharmacologic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
that  	that  	 IN	O
combine  	combine  	 JJ	B-NP
serotonergic  	serotonergic  	 NN	I-NP
and  	and  	 CC	O
noradrenergic  	noradrenergic  	 JJ	B-NP
reuptake  	reuptake  	 JJ	I-NP
inhibition 	inhibition 	 NN	I-NP
,  	,  	 ,	O
thus  	thus  	 RB	O
augmenting  	augmenting  	 VB	O
the  	the  	 DT	O
function  	function  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
neurotransmitters 	neurotransmitters 	 NN	B-NP
,  	,  	 ,	O
have  	have  	 VBP	O
stronger  	stronger  	 JJR	O
analgesic  	analgesic  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
than  	than  	 IN	O
agents  	agents  	 NNS	O
that  	that  	 WDT	O
inhibit  	inhibit  	 VBP	O
reuptake  	reuptake  	 VBN	O
of  	of  	 IN	O
either  	either  	 DT	O
neurotransmitter  	neurotransmitter  	 NN	B-NP
alone 	alone 	 RB	O
.  	.  	 .	O
Although  	Although  	 IN	O
tricyclic  	tricyclic  	 JJ	B-NP
antidepressants  	antidepressants  	 NNS	I-NP
( 	( 	 -LRB-	O
TCAs 	TCAs 	 NNP	B-NP
)  	)  	 -RRB-	O
inhibit  	inhibit  	 VBP	O
reuptake  	reuptake  	 VBN	O
of  	of  	 IN	O
both  	both  	 DT	O
serotonin  	serotonin  	 NN	B-NP
and  	and  	 CC	O
norepinephrine  	norepinephrine  	 NNS	B-NP
and  	and  	 CC	O
have  	have  	 VBP	O
shown  	shown  	 VBN	O
efficacy  	efficacy  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
fibromyalgia 	fibromyalgia 	 NN	B-NP
,  	,  	 ,	O
long-term  	long-term  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
drugs  	drugs  	 NNS	O
is  	is  	 VBZ	O
limited  	limited  	 VBN	O
owing  	owing  	 VBG	O
to  	to  	 TO	O
poor  	poor  	 JJ	O
tolerability 	tolerability 	 NN	B-NP
.  	.  	 .	O
Unlike  	Unlike  	 IN	O
TCAs 	TCAs 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
newer  	newer  	 JJR	O
dual  	dual  	 JJ	B-NP
reuptake  	reuptake  	 JJ	I-NP
inhibitors  	inhibitors  	 NN	I-NP
of  	of  	 IN	I-NP
serotonin  	serotonin  	 NN	I-NP
and  	and  	 CC	O
norepinephrine 	norepinephrine 	 NN	B-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
the  	the  	 DT	O
drugs  	drugs  	 NNS	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	B-NP
and  	and  	 CC	I-NP
Drug  	Drug  	 NNP	I-NP
Administration  	Administration  	 NNP	I-NP
( 	( 	 -LRB-	O
FDA 	FDA 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
fibromyalgia 	fibromyalgia 	 NN	B-NP
,  	,  	 ,	O
milnacipran  	milnacipran  	 NN	B-NP
and  	and  	 CC	O
duloxetine 	duloxetine 	 NN	B-NP
,  	,  	 ,	O
do  	do  	 VBP	O
not  	not  	 RB	O
possess  	possess  	 VB	O
significant  	significant  	 JJ	O
affinity  	affinity  	 NN	B-NP
for  	for  	 IN	O
other  	other  	 JJ	O
neurotransmitter  	neurotransmitter  	 JJ	B-NP
systems 	systems 	 NNS	I-NP
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
diminished  	diminished  	 JJ	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
and  	and  	 CC	O
enhanced  	enhanced  	 JJ	O
tolerability 	tolerability 	 NN	B-NP
.  	.  	 .	O
Both  	Both  	 DT	O
duloxetine  	duloxetine  	 NN	B-NP
and  	and  	 CC	O
milnacipran  	milnacipran  	 NNS	B-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
efficacy  	efficacy  	 VBN	O
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
by  	by  	 IN	O
improving  	improving  	 VBG	B-NP
pain  	pain  	 NN	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
symptoms  	symptoms  	 NNS	B-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
fibromyalgia 	fibromyalgia 	 NN	B-NP
.  	.  	 .	O
Both  	Both  	 DT	O
compounds  	compounds  	 NNS	O
inhibit  	inhibit  	 VBP	O
the  	the  	 DT	O
serotonin  	serotonin  	 NN	B-NP
and  	and  	 CC	O
norepinephrine  	norepinephrine  	 JJ	B-NP
transporters 	transporters 	 NN	I-NP
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
difference  	difference  	 NN	O
in  	in  	 IN	O
their  	their  	 PRP$	O
affinities  	affinities  	 NNS	O
and  	and  	 CC	O
selectivity  	selectivity  	 NN	O
for  	for  	 IN	O
these  	these  	 DT	O
transporters 	transporters 	 NN	B-NP
.  	.  	 .	O
Although  	Although  	 IN	O
duloxetine  	duloxetine  	 NN	B-NP
has  	has  	 VBZ	O
affinity  	affinity  	 VBN	B-NP
for  	for  	 IN	O
both  	both  	 DT	O
receptors 	receptors 	 NN	B-NP
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
somewhat  	somewhat  	 RB	O
more  	more  	 RBR	O
selective  	selective  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
serotonin  	serotonin  	 JJ	B-NP
transporter 	transporter 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
contrast 	contrast 	 NN	O
,  	,  	 ,	O
milnacipran  	milnacipran  	 NN	B-NP
is  	is  	 VBZ	O
somewhat  	somewhat  	 RB	O
more  	more  	 RBR	O
selective  	selective  	 JJ	O
for  	for  	 IN	O
norepinephrine  	norepinephrine  	 NN	B-NP
than  	than  	 IN	O
serotonin  	serotonin  	 JJ	B-NP
reuptake  	reuptake  	 JJ	I-NP
inhibition 	inhibition 	 NN	I-NP
.  	.  	 .	O
Pharmacologic  	Pharmacologic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
that  	that  	 WDT	O
specifically  	specifically  	 RB	O
target  	target  	 VB	O
serotonin  	serotonin  	 NNS	B-NP
and  	and  	 CC	O
norepinephrine  	norepinephrine  	 JJ	B-NP
reuptake  	reuptake  	 NN	I-NP
may  	may  	 MD	O
prove  	prove  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
valuable  	valuable  	 JJ	O
tools  	tools  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
fibromyalgia 	fibromyalgia 	 NN	B-NP
.  	.  	 .	O
